Pharmaceutical Technology on MSN5d
AstraZeneca and Alteogen agree on ALT-B4 platform tech"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
The Chosun Ilbo on MSN4d
S. Korea's biotech sector kicks off 2025 with multi-billion-dollar dealsS. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.
AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform ...
AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...
Cambridge: AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback